Get the Stockscreener App
3.00
1.64%
-0.05
After Hours:
3.0063
0.0063
+0.21%
Celularity Inc stock is currently priced at $3.00, with a 24-hour trading volume of 32,761.
It has seen a -1.64% decreased in the last 24 hours and a -9.37% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.15 pivot point. If it approaches the $2.90 support level, significant changes may occur.
Previous Close:
$3.05
Open:
$3.06
24h Volume:
32,761
Market Cap:
$65.35M
Revenue:
$14.79M
Net Income/Loss:
$-181.41M
P/E Ratio:
-6.1224
EPS:
-0.49
Net Cash Flow:
$-68.18M
1W Performance:
+1.69%
1M Performance:
-9.37%
6M Performance:
+1,330%
1Y Performance:
+466.04%
1D Range:
$3.00
$3.2253
52W Range:
$0.159
$7.97
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
609 235 1010
Address
170 Park Avenue, Florham Park
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
GlobeNewswire Inc.
Celularity announces publication on benefits of placental circulating T cells - TipRanks.com - TipRanks
TipRanks
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for ... - Afternoon Headlines
Afternoon Headlines
Celularity Inc. (NASDAQ:CELUW) Sees Large Growth in Short Interest - Defense World
Defense World
Short Interest in Celularity Inc. (NASDAQ:CELU) Expands By 51.4% - MarketBeat
MarketBeat
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Celularity, Inc. (CELU) - Yahoo Singapore News
Yahoo Singapore News
Celularity Inc Stock (CELU) Financials Data
Celularity Inc (CELU) Revenue 2024
CELU reported a revenue (TTM) of $14.79 million for the quarter ending September 30, 2023, a -20.93% decline year-over-year.
Celularity Inc (CELU) Net Income 2024
CELU net income (TTM) was -$181.41 million for the quarter ending September 30, 2023, a -1,170% decrease year-over-year.
Celularity Inc (CELU) Cash Flow 2024
CELU recorded a free cash flow (TTM) of -$68.18 million for the quarter ending September 30, 2023, a +53.65% increase year-over-year.
Celularity Inc (CELU) Earnings per Share 2024
CELU earnings per share (TTM) was -$10.20 for the quarter ending September 30, 2023, a -537.50% decline year-over-year.
About Celularity Inc
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic T cell therapies. It operates through Cell Therapy, Degenerative Disease, and BioBanking. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T therapy, which is in pre-clinical stage for the treatment of B-cell malignancies; CYNK-001, an allogeneic unmodified natural killer (NK) cell that is in Phase 1 clinical trial to treat acute myeloid leukemia, as well as in Phase 1/2a clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell to treat HER2+ gastric cancer; and APPL-001, a placenta-derived mesenchymal-like adherent stromal cell for the treatment of crohn's disease. The company also sells and licenses products used in surgical and wound care markets, such as Biovance and Interfyl; and collects stem cells from umbilical cords and placentas and provides cells storage under the LifebankUSA brand. Celularity Inc. was incorporated in 2016 and is based in Florham Park, New Jersey.
0.77%
1.20%
Cap:
|
Volume (24h):